FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147627498> ?p ?o ?g. }

• W2147627498 endingPage "1429" @default.
• W2147627498 startingPage "1425" @default.
• W2147627498 abstract "The aim of this phase II study was to determine toxicity, response rate, time to progression, and overall survival of cisplatin, etoposide and gemcitabine in patients with carcinoma of unknown primary tumour site.Thirty patients with no previous chemotherapy and not belonging to a treatable group were treated with cisplatin 70 mg/m(2) on day 1, etoposide 70 mg/m(2) on days 1 and 2, and gemcitabine 700 mg m(2) on days 1 and 8, administered every 3 weeks. Stable or responding patients received a maximum of eight cycles. Twenty patients (67%) had more than three affected sites, and 25 patients (84%) had adenocarcinomas.Overall response rate was 36.6% (11 patients), including four complete responses (13.3%) and seven partial responses (23.3%), with a 95% confidence interval of 19.9-56. Median survival was 7.21 months and eight patients remained alive for >1 year. Myelosuppression was the most important toxicity, with grade 3-4 neutropenia in 18 patients (60%) in 32% of the cycles: eight patients had neutropenic fever and 10 patients had thrombopenia in 11% of cycles. No non-haematological grade 4 toxicity occurred.Cisplatin, etoposide and gemcitabine is an active combination, inducing objective responses in a subset of heavily advanced disease patients with carcinoma of unknown primary site. The role of adding gemcitabine to cisplatin and etoposide remains to be resolved as to the best schedule to diminish toxicity for the three-drug combination." @default.
• W2147627498 created "2016-06-24" @default.
• W2147627498 creator A5005273655 @default.
• W2147627498 creator A5005995857 @default.
• W2147627498 creator A5024309839 @default.
• W2147627498 creator A5044887899 @default.
• W2147627498 creator A5055002084 @default.
• W2147627498 creator A5064537141 @default.
• W2147627498 creator A5064917327 @default.
• W2147627498 creator A5065964233 @default.
• W2147627498 date "2003-09-01" @default.
• W2147627498 modified "2023-10-18" @default.
• W2147627498 title "A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site" @default.
• W2147627498 cites W1818021918 @default.
• W2147627498 cites W1875461519 @default.
• W2147627498 cites W1878896819 @default.
• W2147627498 cites W1908498093 @default.
• W2147627498 cites W1913120928 @default.
• W2147627498 cites W1931508686 @default.
• W2147627498 cites W1983333559 @default.
• W2147627498 cites W1999325096 @default.
• W2147627498 cites W2007032311 @default.
• W2147627498 cites W2008309443 @default.
• W2147627498 cites W2022391865 @default.
• W2147627498 cites W2036610593 @default.
• W2147627498 cites W2066106964 @default.
• W2147627498 cites W2070584753 @default.
• W2147627498 cites W2083060857 @default.
• W2147627498 cites W2094767885 @default.
• W2147627498 cites W2104521005 @default.
• W2147627498 cites W2135352785 @default.
• W2147627498 cites W2166550667 @default.
• W2147627498 cites W2167122324 @default.
• W2147627498 cites W2285683947 @default.
• W2147627498 cites W2322693032 @default.
• W2147627498 cites W4232782355 @default.
• W2147627498 cites W4233839029 @default.
• W2147627498 doi "https://doi.org/10.1093/annonc/mdg361" @default.
• W2147627498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12954583" @default.
• W2147627498 hasPublicationYear "2003" @default.
• W2147627498 type Work @default.
• W2147627498 sameAs 2147627498 @default.
• W2147627498 citedByCount "23" @default.
• W2147627498 countsByYear W21476274982012 @default.
• W2147627498 countsByYear W21476274982013 @default.
• W2147627498 countsByYear W21476274982017 @default.
• W2147627498 countsByYear W21476274982020 @default.
• W2147627498 countsByYear W21476274982022 @default.
• W2147627498 countsByYear W21476274982023 @default.
• W2147627498 crossrefType "journal-article" @default.
• W2147627498 hasAuthorship W2147627498A5005273655 @default.
• W2147627498 hasAuthorship W2147627498A5005995857 @default.
• W2147627498 hasAuthorship W2147627498A5024309839 @default.
• W2147627498 hasAuthorship W2147627498A5044887899 @default.
• W2147627498 hasAuthorship W2147627498A5055002084 @default.
• W2147627498 hasAuthorship W2147627498A5064537141 @default.
• W2147627498 hasAuthorship W2147627498A5064917327 @default.
• W2147627498 hasAuthorship W2147627498A5065964233 @default.
• W2147627498 hasBestOaLocation W21476274981 @default.
• W2147627498 hasConcept C126322002 @default.
• W2147627498 hasConcept C141071460 @default.
• W2147627498 hasConcept C143998085 @default.
• W2147627498 hasConcept C2776694085 @default.
• W2147627498 hasConcept C2777063308 @default.
• W2147627498 hasConcept C2778119113 @default.
• W2147627498 hasConcept C2778239845 @default.
• W2147627498 hasConcept C2780258809 @default.
• W2147627498 hasConcept C29730261 @default.
• W2147627498 hasConcept C31760486 @default.
• W2147627498 hasConcept C71924100 @default.
• W2147627498 hasConcept C90924648 @default.
• W2147627498 hasConceptScore W2147627498C126322002 @default.
• W2147627498 hasConceptScore W2147627498C141071460 @default.
• W2147627498 hasConceptScore W2147627498C143998085 @default.
• W2147627498 hasConceptScore W2147627498C2776694085 @default.
• W2147627498 hasConceptScore W2147627498C2777063308 @default.
• W2147627498 hasConceptScore W2147627498C2778119113 @default.
• W2147627498 hasConceptScore W2147627498C2778239845 @default.
• W2147627498 hasConceptScore W2147627498C2780258809 @default.
• W2147627498 hasConceptScore W2147627498C29730261 @default.
• W2147627498 hasConceptScore W2147627498C31760486 @default.
• W2147627498 hasConceptScore W2147627498C71924100 @default.
• W2147627498 hasConceptScore W2147627498C90924648 @default.
• W2147627498 hasIssue "9" @default.
• W2147627498 hasLocation W21476274981 @default.
• W2147627498 hasLocation W21476274982 @default.
• W2147627498 hasOpenAccess W2147627498 @default.
• W2147627498 hasPrimaryLocation W21476274981 @default.
• W2147627498 hasRelatedWork W1904937717 @default.
• W2147627498 hasRelatedWork W1970921743 @default.
• W2147627498 hasRelatedWork W1972888300 @default.
• W2147627498 hasRelatedWork W2008288458 @default.
• W2147627498 hasRelatedWork W2100029565 @default.
• W2147627498 hasRelatedWork W2147627498 @default.
• W2147627498 hasRelatedWork W2371822093 @default.
• W2147627498 hasRelatedWork W2381460883 @default.
• W2147627498 hasRelatedWork W2419166579 @default.
• W2147627498 hasRelatedWork W2616578431 @default.

• next